Coeptis Therapeutics Raises $10 Million for AI-Driven Innovations

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) has successfully closed an additional $5.7 million in its final Series A Preferred Offering, bringing the total financing round to $10 million. This financing, led by CJC Investment Trust, reflects strong investor confidence in Coeptis' innovative biotechnology and AI-driven therapeutic solutions. The funds will be used to enhance operational capabilities and support the company's strategic pivot towards technology integration, particularly through the recent acquisition of the NexGenAI Affiliates Network platform. The Series A Preferred shares are convertible at a price of $8.00 per share and carry a 15% equity interest in newly formed subsidiaries. Despite this financing success, COEP shares experienced a slight decline of 1% to $10.18. Overall, the company's focus on advanced AI solutions aims to improve marketing and operational efficiencies in the biopharmaceutical sector.